Phillips-Medisize Increases Global Manufacturing Capacity, Capabilities and Collaborations to Drive Drug Delivery, Diagnostic and MedTech Innovations
PR92430
HUDSON, Wis., Oct. 19, 2021 /PRNewswire=KYODO JBN/ --
- Medical and pharmaceutical solutions leader poised to scale manufacturing
from new and expanded production facilities and R&D centers in Poland, China
and U.S.
- End-to-end capabilities optimize design, development and manufacturing of
world-class healthcare products and solutions while reducing time, cost and risk
- Industry-leading collaborations with Eyevensys, GlucoModicum and Credence
MedSystems accelerate delivery of technology breakthroughs and next-gen products
a Molex company and leader in the design and manufacture of drug delivery,
diagnostic and MedTech devices, announces the expansion of its global
manufacturing footprint, along with extended product design, development and
manufacturing capabilities to streamline the delivery of game-changing products
and solutions. The company's global reach now encompasses 36 world-class
facilities with scalable, end-to-end capabilities tailored to help customers
bring groundbreaking products to market quickly and efficiently from anywhere
in the world.
Photo -
https://mma.prnewswire.com/media/1663581/Growing_footprint_of_Phillips_Medisize.jpg
"As the preferred partner for leading global customers, we continually invest
in new talent and technologies that increase the capacity and capabilities of
Phillips-Medisize across the entire value chain," said Paul Chaffin, president,
Medical and Pharmaceutical Solutions, Molex. "Our expanded global reach and
resources will enable us to solve complex development and manufacturing
challenges while meeting escalating customer demands for more localized
production, supply chain management and accelerated go-to-market strategies."
Growing Footprint for Local Support, Global Scale
To address growing production demands from customers in continental Europe,
Phillips-Medisize is building a state-of-the-art medical manufacturing facility
in Katowice, Poland. Slated to open in 2022, the site will complement
production sites and innovation centers in Asia, Europe, India, Mexico and
North America. Phillips-Medisize also is expanding production capacity in
Suzhou, China to serve both global and regional pharmaceutical and MedTech
customers. Additionally, the transformation of an existing Molex production
facility in Little Rock, Ark., is underway, enabling Phillips-Medisize to keep
pace with ever-increasing requirements in the U.S. for high-volume, diagnostic
device manufacturing.
Once these expansions are complete, Phillips-Medisize will offer nearly three
million square feet/280,000 square meters of country- and region-specific
manufacturing space and R&D capabilities worldwide. The company also will
support 600,000 square feet/55,000 square meters of Class 7 and 8 cleanrooms,
which complement existing tool building sites as well as global quality and
regulatory systems. In 2020, Phillips-Medisize completed a new facility in St.
Croix Meadows, Wisc., with 285,000 square feet/26,000 square meters supporting
production of molded components for medical diagnostic customers requiring
high-volume assembly and packaging of regulated products. The facility also
includes a nearly 64,000 square-foot/6,000 square-meter ISO 14644-1 Class 8
cleanroom.
Extending End-to-End Capabilities
As part of its one-stop shop of medical-device manufacturing solutions,
Phillips-Medisize focuses on design for manufacturability and assembly
excellence. Proven front-end innovation, human-factors engineering, and quality
are integrated with regulatory adherence to reduce go-to-market risk and cost.
Expanded capabilities in complex molding, drug and reagent handling, as well as
final packaging and serialization, enable customers to consolidate global
supply chains while optimizing go-to-market strategies.
Phillips-Medisize's combined expertise in plastics, metals, electronics and
connectivity ease the development of different solutions, including combination
devices such as needle-based injection systems and wearable injection
technologies. An unwavering commitment to rigorous quality management is
reinforced by dedicated New Product Introduction (NPI) teams at every site.
Strategic investments in talent acquisition to support Phillips-Medisize's
continued growth are expected to add at least 1,000 employees worldwide over
the next couple of years.
Optimizing Industry-Leading Collaborations
A strong track record of collaboration ensures Phillips-Medisize is at the
forefront of the latest advancements in drug delivery, diagnostic and MedTech
devices. Today, Credence MedSystems announced (https://c212.net/c/link/?t=0&l=en&o=3327347-1&h=122506672&u=https%3A%2F%2Fwww.credencemed.com%2Fabout%2Fnews%2F%23tab3&a=Credence+MedSystems+announced) a strategic initiative with Phillips-Medisize (https://c212.net/c/link/?t=0&l=en&o=3327347-1&h=673569949&u=https%3A%2F%2Fexperience.molex.com%2Ffortifying-healthcare-innovation-from-the-frontlines%2F%3Futm_source%3Dpress-outreach%26utm_medium%3Dprrelease%26utm_content%3DBlog%2Bfrom%2BPhillpis%2BExpansion%2BPress%2BRelease%2B%26utm_campaign%3D7018W000000inIsQAI&a=strategic+initiative+with+Phillips-Medisize) that includes ramping production of the Credence Companion(R) and Dual
Chamber Reconstitution Systems at the Phillips-Medisize Letterkenny, Ireland
site and the new facility in Poland.
"We're excited to leverage Phillips-Medisize's world-class manufacturing as we
scale toward high-volume automation at the new state-of-the-art facility in
Poland," said Jeff Tillack, COO at Credence MedSystems. "The opportunity to
scale production in close proximity to our operations and European customers
will accelerate market delivery of our innovative solutions to meet the needs
of our pharma customers and their end-users."
In September, GlucoModicum entered into a design and development program
with Phillips-Medisize for the rapid scale-up of manufacturing for its
Talisman needle-free continuous glucose monitor, which uses unique
magnetohydrodynamic (MHD) technology. Also last month, Paris-based Eyevensys
announced an engagement (https://c212.net/c/link/?t=0&l=en&o=3327347-1&h=3673616776&u=https%3A%2F%2Fwww.eyevensys.com%2Feyevensys-enters-collaboration-with-phillips-medisize-and-minnetronix-medical%2F&a=Eyevensys+announced+an+engagement) with Phillips-Medisize to optimize the design, development and high-volume
manufacturing of its ocular device component that powers the delivery of novel
gene therapies for treating various eye diseases.
Phillips-Medisize Brings Possibilities to Life
Phillips-Medisize, a Molex company, brings decades of innovation to leading
healthcare and life science companies to develop groundbreaking solutions that
help people live healthier, more productive lives. On average, the company
commercializes 50 new products a year for customers, including the
first-to-market FDA-registered drug-delivery device utilizing a connected
health system. Molex brings decades of experience in advanced electronics,
connectivity and sensor technologies to help transform medical and
pharmaceutical solutions.
About Molex
Molex is a global electronics leader committed to making the world a better,
more-connected place. With presence in more than 40 countries, Molex enables
transformative technology innovation in the automotive, data center, industrial
automation, healthcare, 5G, cloud and consumer device industries. Through
trusted customer and industry relationships, unrivaled engineering expertise,
and product quality and reliability, Molex realizes the infinite potential of
Creating Connections for Life. For more information, visit www.molex.com.
SOURCE Molex
CONTACT: Sue Hetzel, HetzelMeade Communications, on behalf of Molex,
sue@hetzelmeade.com, 760.473.4729
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。